Chiesi Farmaceutici S.p.A. Company Profile

22:36 EDT 21st March 2018 | BioPortfolio

Chiesi Pharmaceuticals, which started up in 1935 as a small family company is today an international company in the pharmaceutical sector and operates in all 5 continents with 24 direct branches, 3 manufacturing plants and 4 research centres situated in Parma (Italy), Paris, Rockville (Maryland - USA) and Chippenham (UK). The Company's history of continual development is founded on concepts which constitute the basis for its management: strategic innovation, internationalization and ability to plan taking care in the creation of socially compatible economic values.


Thanks to the process of internationalization and strategic alliances with international pharmaceutical groups, Chiesi Group drugs and technologies are today distributed in over 65 countries. The Group employs over 3,800 people, approximately 320 of whom are researchers who work in the four Research and Development laboratories, and approximately 600 of whom are employed in the manufacturing sites in Italy, France and Brazil.

Our Mission


  • Our aim is to be recognised as a research-focused international Group, able to develop and commercialise innovative pharmaceutical solutions to improve the quality of human life.
  • We want to maintain a high quality entrepreneurial team characterised by self confidence and a collaborative spirit.
  • Our goal is to combine commitment to results with integrity, operating in a socially and environmentally responsible manner


Via Palermo, 26/A


Phone: +39 0521 279
Fax: +39 0521 774468

News Articles [37 Associated News Articles listed on BioPortfolio]

Protalix gives Chiesi ex-US rights to Fabry's disease treatment

Chiesi Farmaceutici gained ex-US rights to Protalix BioTherapeutics' PRX-102, or pegunigalsidase alfa, which is in late-stage -More- 

Chiesi gets ex-US rights to Protalix's Phase III Fabry candidate

Protalix BioTherapeutics Inc. licensed Chiesi Farmaceutici SPA exclusive rights to develop and commercialize its Phase III PRX102 (pegunigalsidase alfa) for Fabry disease in all territories except the...

Protalix BioTherapeutics Enters into an Exclusive Ex-US Partnership with Chiesi Farmaceutici for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease

Protalix grants Chiesi Ex-US rights to PRX-102, a chemically modified version of the recombinant protein alpha-Galactosidase-A protein Protalix to receive $25 million upfront, an additional up to...

Pending EC decision: CHF 5993 Chiesi Farmaceutici S.p.A., beclometasone dipropionate anhydrous / formoterol fumarate dihydrate / glycopyrronium, Opinion date: 22-Feb-2018

Kamada, Chiesi Farmaceutici Terminate Inhaled Alpha-1 Antitrypsin Therapy Deal

Kamada now maintains full, worldwide commercial rights to its inhaled AAT.

Kamada and Chiesi Farmaceutici S.p.A. Mutually Agree to Terminate European Distribution Agreement for Inhaled Alpha-1 Antitrypsin Therapy for Treatment of Alpha-1 Antitrypsin Deficiency

Following Kamada’s Recent Withdrawal of European Marketing Authorization Application, Distribution Agreement Not Currently Warranted REHOVOT, Israel, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Kamada ...

EU Panel Backs Two Triple Combo Drugs for COPD Maintenance

CHF 5993 and Trydonis, from Chiesi Farmaceutici SpA, combine a glucocorticoid, a long-acting beta-2 receptor agonist, and a long-acting muscarinic antagonist. International Approvals

Chiesi USA Breaks Ground on New Headquarters Building in Cary

CARY, NC--(Marketwired - November 02, 2017) - Chiesi USA, a specialty pharmaceutical company focused on the hospital, rare disease, and hospital-adjacent settings, broke ground today on a new corporat...

Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Curosurf [Cornerstone Therapeutics Inc.]

CUROSURF (poractant alfa)Intratracheal Suspension

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Experimental and computational study of the effect of breath-actuated mechanism built in the NEXThaler(®) dry powder inhaler.

The breath-actuated mechanism (BAM) is a mechanical unit included in NEXThaler(®) with the role of delaying the emission of the drug until the inhalation flow rate of the patient is sufficiently high...

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma

The purpose of this trial is to verify if the test treatment BDP 250 mcg/salbutamol 100 mcg HFA pMDI fixed combination is non-inferior to BDP 250 mcg/salbutamol 100 mcg pMDI fixed combina...

Evaluation of the Filler Performance on the Nasolabial Folds of Aliaxin® EV With and Without Lidocaine 0.3%

Evaluation of the filler performance on the nasolabial folds of Aliaxin® EV with and without lidocaine 0.3%: comparison within subjects (half face method)

Evaluation of the Re-volumizing Performance of Aliaxin (New Trademark)

Aim of the study is to evaluate the re-volumizing performance and the duration effect of the product Aliaxin (new trademark) in women aged 40-65 years with midface volume defects due to ag...

Early Viscosupplementation After Partial Meniscectomy: a Randomized Controlled Trial

The rational of intra-articular viscosupplementation is based on both the biological and mechanical properties of HA, which exerts positive effects on the modulation of the entire joint en...

Companies [6 Associated Companies listed on BioPortfolio]

Chiesi Farmaceutici S.p.A.

Chiesi Pharmaceuticals, which started up in 1935 as a small family company is today an international company in the pharmaceutical sector and operates in all 5 continents with 24 direct branches, 3 ...

Chiesi Group

The Company, founded in Parma in 1935, is today an international reality in the pharmaceutical market. With global operations consisting of 21 direct affiliates, 3 manufacturing sites, and 3 research ...

Mediolanum farmaceutici S.p.A


Dompé Farmaceutici S.p.A.

Dompé is one of the most dynamic, flexible and innovative set-ups on the European scene.Successful in the traditional pharmaceutical market in the treatment of respiratory and osteoarticular patholog...

Fidia Pharma USA Inc.

Fidia Pharma USA Inc., headquartered in Parsippany, NJ, is a wholly-owned subsidiary of the multinational pharmaceutical company Fidia Farmaceutici SpA. Fidia Pharma USA is focuse...

More Information about "Chiesi Farmaceutici S.p.A." on BioPortfolio

We have published hundreds of Chiesi Farmaceutici S.p.A. news stories on BioPortfolio along with dozens of Chiesi Farmaceutici S.p.A. Clinical Trials and PubMed Articles about Chiesi Farmaceutici S.p.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chiesi Farmaceutici S.p.A. Companies in our database. You can also find out about relevant Chiesi Farmaceutici S.p.A. Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record